Cases with high tumor mutation burden (TMB, see the distributions of TMBs in Supplementary Figure S1) and low TGF-β expression were defined as responsive to ICI (positive) and the others as without responsiveness (negative) as previously suggested (Methods, see Supplementary Figure S2A for the number of cases marked as positive in each tumor type) (27–29, 32) since large pan-cancer tumor immunotherapy cohort with DNA methylation level measured was lacking. Here, TGFB1 is linked to cancer.